Nasdaq GlobeNewswire

Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership

Del

RENSSELAER, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership.  Under the agreement terms, the two companies will combine resources to provide the global scientific community with access to premium custom model design and generation services backed by comprehensive capabilities and cutting-edge, fully-licensed technologies.

Custom animal models play a critical role in new drug discovery as biological systems that provide critical insight into the dynamic between a potential therapeutic and a living organism.

Combining over twenty years of experience, the industry's most extensive model generation technology portfolio, and seamless integration to downstream premium custom breeding solutions, Taconic is recognized for creating complex genetically engineered mice and rats for biomedical research. Cyagen entered the industry in 2005 and has gained a strong following for providing model and vector generation services. Through the alliance, Cyagen customers gain access to expanded expertise, comprehensive program management, state-of-the art technologies, pricing flexibility, and faster project timelines through a single point of contact, ensuring the best solution for each unique project. 

"Taconic will provide the best solution to every model generation customer through access to scientific experts who generate superior designs using state-of-the-art methods.  Through this alliance with Cyagen, Taconic can now offer customers the broadest range of options in the industry in line with market demand," shared Dr. Robert Rosenthal, CEO of Taconic Biosciences. 

"Cyagen Biosciences provides researchers with the highest quality animal models possible to ensure ground breaking discoveries.  Researchers are increasingly demanding higher quality animal model services at lower costs. Through this new alliance with Taconic, Cyagen will offer researchers even higher quality animal models, with new options available to minimize or eliminate quarantine and other added costs, while providing production capabilities that exceed previous standards and expectations," commented Dr. Reza Rezaei, VP of Sales of Cyagen Biosciences.

To learn more about Taconic Biosciences' products and services, please call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

To learn more about Cyagen Biosciences, please call 800-921-8930 (from 8 a.m. - 6 p.m. PST) or +1-408-969-0306 (Int'l) in the US, 800-793-45 or +32-28085797 (Int'l) in Europe, or email service@cyagen.com.

About Cyagen Biosciences, Inc.
Cyagen Biosciences is the world's largest provider of custom-engineered mouse & rat models. Cyagen is world renowned for its quality, money back guarantee, and cost-effective prices. Headquartered in California, with locations in Germany, Japan, and China, Cyagen provides researchers from around the world with transgenic, knockout, knock-in, CRISPR, and ES-cell based models and also offers a comprehensive series of stem cell products for research use, including cell lines, media, and differentiation kits. From vector and strategy design to animal model creation, cryopreservation, and breeding, Cyagen offers complete outsourcing for all animal model needs.

About Taconic Biosciences, Inc.
Taconic Biosciences is a global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal model solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Taconic is a fully-licensed provider of rodent model generation services and has twenty years of model design experience, providing gene inactivation, gene mutation, replacement and humanization, transgene expression, RNAi, and gene editing via CRISPR/Cas9 technologies to ensure that the right tools are leveraged for each specific customer project.  Complimenting this expertise is Taconic's unique capability of providing a seamless transition from model design to breeding and colony management, thus offering customers a complete solution.  Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
Taconic Biosciences 
(518) 697-3824
kelly.grover@taconic.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

DoubleVerify and InMobi Unite to Combat Mobile App Fraud11.12.2018 18:02Pressemelding

Partnership brings mobile app fraud prevention to advertisers globally NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DoubleVerify ("DV"), the leading independent provider of marketing measurement software and analytics, today announced a partnership with InMobi, a global provider of enterprise platforms for marketers. As part of the partnership, DoubleVerify will provide always-on fraud filtering and measurement for mobile in-app advertising campaigns across the InMobi Exchange globally. The integration with InMobi covers pre-bid targeting for all InMobi Exchange impressions within the leading mobile in-app platform, as well as monitoring of post-bid fraud activity, such as spoofing – enabling InMobi to continuously refine the quality of its mobile ad inventory. “DV’s partnership with InMobi demonstrates our commitment to provide consistent, comprehensive quality coverage for global brand advertisers,” said Matt McLaughlin, COO at DoubleVerify. “With ad spend increasingly concentrated in

Claroty Announces Major Enhancements to Market-Leading Industrial Cybersecurity Platform11.12.2018 15:00Pressemelding

Groundbreaking multispectral data acquisition and network segmentation capabilities provide deeper OT network visibility and reduce risk for industrial enterprises and critical infrastructure providers NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network protection, today announced several significant enhancements to its award-winning Continuous Threat Detection product and technology integrations with several leading industrial automation, network infrastructure and cybersecurity providers. Already the industry’s most complete industrial control systems (ICS) cybersecurity platform, this release incorporates new functionality to provide even more “extreme” visibility into ICS networks and help industrial enterprises decrease the risk of a cyberattack. The latest release of Claroty Continuous Threat Detection provides a large number of significant enhancements including: Virtual Zones and OT Network Segmentation – an innovative approach

INN Launches Battery Metals Channel11.12.2018 15:00Pressemelding

The new battery metals channel is designed to educate investors with original content and expert insight on the growing battery metals industry. VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Investing News Network (INN) announces the launch of its battery metals channel. Responding to the growth and evolution of the battery metals market, this channel will host news, educational content and expert opinions on the lithium, cobalt, graphite, vanadium and manganese market segments. “INN has been a trusted source of information on the lithium, cobalt, graphite, vanadium and manganese markets for nearly a decade, and is excited to bring these sectors together under the battery metals umbrella,” said Nick Smith, CEO and publisher at INN. “Through connections with experts, our leading team of experienced writers creates original, insightful content on battery metals. INN educates investors in the industry by providing information they may never have access to on their own,” S

Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer11.12.2018 14:30Pressemelding

KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the appointment of Hermann Russ, M.D., Ph.D., as its chief scientific officer, effective December 1, 2018. Dr. Russ invented the use of the company’s lead molecule GAL-101/MRZ-99030 for the treatment of degenerative diseases of the retina, including glaucoma and dry macular degeneration. He is also co-inventor of the so-called “trigger effect” of GAL-101/MRZ-99030 and GAL-102/MRZ 14042, which is a unique reverse prion-like self-propagation mechanism of action important for the company’s eye drop and oral treatment regimens. “We are gratified that Dr. Russ is joining the Galimedix management team, as his knowledge in the field, as well as intimate experience with the compound, have already proven instrumental in the development of our company to date,” commented Andrew Pearlman, Ph.D., CEO of Galimedix

Farmako: Cannabis distributor to become gateway to Europe11.12.2018 10:00Pressemelding

Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research and development FRANKFURT, Germany, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Frankfurt-based pharmaceutical company Farmako is a research-based pharmaceutical company that distributes medical cannabis. The company is active in all European markets that have created a legal basis for cannabinoid therapies. It is the first company for medical Cannabis pursue distribution licences in multiple European countries. Fort hat, it will rely on EU-GMP certified suppliers. The German market for medical cannabis is estimated at 19.1 million euros in 2018 and at 200 million Euros by 2019. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400. The number of patients for cannabinoid therapies in Germany has grown from

Kofax RPA Wins DM Award for Artificial Intelligence / Robotic Process Automation Product of the Year11.12.2018 09:00Pressemelding

Recognised as Finalist in Seven Categories, Kofax Named Leader in New Category Reflecting the Evolution of the Document and Content Management Sector IRVINE, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Kofax ® , a leading supplier of intelligent automation (IA) software to digitally transform end-to-end business processes, today announced Kofax RPA was named “AI / Robotic Process Automation Product of the Year” at the 2018 DM Awards, a prestigious awards program conducted by Document Manager Magazine. “By enabling organisations to easily and cost effectively scale their RPA deployments across the enterprise, we’ve raised the bar with Intelligent Automation – the next generation of RPA. We are pleased that the readers of DM Magazine recognise this and honored to receive this award. It is a testament to our success and leadership in the market,” said Reynolds C. Bish, Chief Executive Officer of Kofax. “As the only vendor with cognitive capture, RPA, process orchestration and analytics in i

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom